Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 10/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802533 | 0.83 | ADORA3 (0.51) | MALT1PHGDHTRPV1KDRGSK3B | |
| SCHEMBL6072197 | 0.83 | CHRM5 (0.45) | CHRM5TRPV1ME3CHRM1HSD17B10 | |
| SCHEMBL5799490 | 0.80 | CHRM5 (0.49) | CHRM5TRPV1ME3CHRM1HSD17B10 | |
| SCHEMBL6072388 | 0.79 | TRPV1 (0.64) | CHRM5TRPV1ME3CHRM1HSD17B10 | |
| SCHEMBL5802788 | 0.78 | PHGDH (0.67) | PHGDHTRPV1HSD17B10 | |
| SCHEMBL6072349 | 0.77 | CHRM5 (0.63) | CHRM5GSK3BME3HSD17B10 | |
| SCHEMBL6072188 | 0.76 | CHRM5 (0.45) | CHRM5TRPV1 | |
| SCHEMBL5798538 | 0.76 | PDE3B (0.46) | CHRM5HSD17B10MMP2ADAMTS5 | |
| SCHEMBL27832334 | 0.73 | GSK3B (0.57) | KDRGSK3BADORA3 | |
| SCHEMBL27305836 | 0.70 | UCHL1 (0.54) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | CHRM5 1551/4885MALT1 2441/4885RIPK2 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.